We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.77%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.73B
AUM Growth
+$1.49B
Cap. Flow
+$225M
Cap. Flow %
2.57%
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
80
Reduced
68
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$143M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$63.9M
3
MRSN
Mersana Therapeutics
MRSN
+$42.8M
4
DXCM icon
DexCom
DXCM
+$32.7M
5
ABBV icon
AbbVie
ABBV
+$32.5M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$154M
2
HALO icon
Halozyme
HALO
+$51.2M
3
CRL icon
Charles River Laboratories
CRL
+$49.6M
4
CDNA icon
CareDx
CDNA
+$44.7M
5
MDT icon
Medtronic
MDT
+$40.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Technology 0.6%
3 Industrials 0.33%
4 Financials 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOCO
126
DELISTED
GoHealth
GOCO
$4.61M 0.05%
22,495
+1,517
+7% +$282K
ZLAB icon
127
Zai Lab
ZLAB
$2.17B
$4.43M 0.05%
32,700
-128,500
-80% -$13.1M
JNJ icon
128
Johnson & Johnson
JNJ
$635B
$4.41M 0.05%
+28,000
New +$4.13M
BNR
129
Burning Rock Biotech
BNR
$94.4M
$4.28M 0.05%
18,529
+3,853
+26% +$1.03M
SEER icon
130
Seer Inc
SEER
$108M
$4.23M 0.05%
+75,336
New +$4.79M
LH icon
131
Labcorp
LH
$24.3B
$3.87M 0.04%
22,154
-40,974
-65% -$7.08M
SRPT icon
132
Sarepta Therapeutics
SRPT
$1.66B
$3.46M 0.04%
20,300
– –
QTNT
133
DELISTED
Quotient Limited Ordinary Shares
QTNT
$3.42M 0.04%
16,434
-6,493
-28% -$1.51M
A icon
134
Agilent Technologies
A
$39.1B
$2.77M 0.03%
23,400
+17,200
+277% +$1.9M
APLS
135
DELISTED
Apellis Pharmaceuticals
APLS
$2.75M 0.03%
+48,000
New +$2.03M
PFE icon
136
Pfizer
PFE
$140B
$2.72M 0.03%
73,900
-3,991
-5% -$146K
MRTX
137
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.7M 0.03%
12,300
-5,500
-31% -$1.19M
ALLK
138
DELISTED
Allakos
ALLK
$2.59M 0.03%
+18,500
New +$1.93M
CHRS icon
139
Coherus Oncology
CHRS
$217M
$2.59M 0.03%
149,000
-1,254,400
-89% -$22.3M
ASND icon
140
Ascendis Pharma A/S
ASND
$16.7B
$2.58M 0.03%
15,500
– –
BMY.RT
141
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$2.5M 0.03%
3,617,446
+2,817,446
+352% +$6M
GTH
142
DELISTED
Genetron Holdings Limited ADS
GTH
$2.45M 0.03%
58,283
+4,813
+9% +$175K
ACAD icon
143
Acadia Pharmaceuticals
ACAD
$4.25B
$2.4M 0.03%
44,900
– –
CLLS
144
Cellectis
CLLS
$286M
$2.26M 0.03%
83,500
– –
KYNB
145
Kyntra Bio
KYNB
$28.5M
$1.97M 0.02%
2,120
– –
KURA icon
146
Kura Oncology
KURA
$922M
$1.89M 0.02%
58,000
+10,000
+21% +$351K
RVMD icon
147
Revolution Medicines
RVMD
$40.2B
$1.58M 0.02%
+40,000
New +$1.58M
XNCR icon
148
Xencor
XNCR
$1.44B
$1.53M 0.02%
+35,100
New +$1.45M
DRNA
149
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.5M 0.02%
+68,000
New +$1.5M
BNTX icon
150
BioNTech
BNTX
$22.6B
$1.47M 0.02%
18,000
-31,500
-64% -$3.09M
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2020 Portfolio in Review

As of Q4 2020, Bellevue Group held 234 positions worth $8.73B, up 21% from $7.24B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group's Q4 2020 filing shows 17 new, 80 increased, 68 reduced and 12 closed positions. Its largest new stake was Mersana Therapeutics: 77,040 shares worth $51.3M. The largest sale was MyoKardia, Inc. Common Stock, an estimated $154M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q4 2020 buy was Mersana Therapeutics: 77,040 shares worth $51.3M.
  • Bellevue Group added most to Biogen in Q4 2020, an estimated $143M increase.
  • Bellevue Group's biggest Q4 2020 reduction was Halozyme, cutting an estimated $51.2M.
  • Bellevue Group fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $154M.
  • Bellevue Group's ten largest holdings make up 32% of its $8.73B portfolio in Q4 2020.
  • Bellevue Group opened 17 new positions and closed 12 in Q4 2020.
  • Bellevue Group's portfolio value rose 21% quarter-over-quarter to $8.73B.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.